Last updated: October 25, 2026
Tavaborole is a topical oxaborole antifungal approved by the FDA as Kerydin 5% topical solution for toenail onychomycosis. Its commercial value depends less on active-ingredient exclusivity than on vehicle performance, nail penetration, adherence, manufacturing cost, generic substitution, and differentiated delivery systems. The reference formulation uses alcohol, propylene glycol, and diethylene glycol monoethyl ether, a solvent system designed to move tavaborole through the nail plate and into the nail bed. [1]
What is tavaborole and how is it marketed?
Tavaborole is a small-molecule boron-containing antifungal. Kerydin is applied once daily to affected toenails for 48 weeks. The product does not require routine nail debridement, which supports its positioning as a prescription alternative to oral terbinafine and to topical products requiring more complex application procedures. [1]
| Attribute |
Tavaborole |
| Brand |
Kerydin |
| Active ingredient |
Tavaborole |
| Strength |
5% w/w topical solution |
| Dosage form |
Nail-applied topical solution |
| FDA approval |
July 2014 |
| Approved indication |
Toenail onychomycosis |
| Treatment duration |
Once daily for 48 weeks |
| Initial developer |
Anacor Pharmaceuticals |
| Acquirer |
Pfizer acquired Anacor in 2016 |
| Administration |
Apply to toenail, nail folds, nail bed, hyponychium and underside of the toenail |
| Regulatory pathway for copies |
ANDA for therapeutically equivalent generic solution, subject to FDA requirements |
The pivotal trials showed complete cure rates of approximately 6.5% to 9.1% at the end of treatment, compared with approximately 0.5% to 1.5% for vehicle. The results support efficacy, but the low complete-cure rate leaves room for products that improve penetration, treatment persistence or combination therapy. [1,2]
What excipients are used in the Kerydin formulation?
The Kerydin vehicle contains alcohol, propylene glycol and diethylene glycol monoethyl ether. The label identifies the product as a clear, colorless solution. [1]
Functional role of each excipient
| Excipient |
Primary formulation role |
Commercial relevance |
| Alcohol |
Volatile solvent and wetting agent |
Improves spreading and rapid drying; can increase sting and dryness |
| Propylene glycol |
Cosolvent, humectant and penetration-supporting vehicle |
Widely available and inexpensive; may cause irritation in sensitive users |
| Diethylene glycol monoethyl ether |
High-performance solvent and skin/nail penetration enhancer |
Supports drug solubilization and transport through keratinized tissue; requires toxicological and regulatory control |
The vehicle is a performance system rather than a simple solvent blend. Tavaborole must remain dissolved during storage, spread over the nail surface, enter the keratinized nail plate and reach the fungal site without creating excessive irritation.
Why the solvent system matters
The nail plate is a dense keratin matrix with limited permeability. A formulation that produces a high drug concentration on the nail surface may still perform poorly if the active ingredient crystallizes, evaporates before penetration or fails to partition into the nail plate.
Diethylene glycol monoethyl ether is commercially important because it can improve the partitioning of small molecules into keratinized tissue. Propylene glycol contributes solvent capacity and hydration. Alcohol lowers viscosity, accelerates drying and improves user perception. The combination balances solubility, application behavior and penetration.
A generic manufacturer that changes the excipient system may need to demonstrate that the substitute formulation remains pharmaceutically equivalent and performs comparably in the relevant regulatory tests. A materially different vehicle can create development risk even when the active ingredient and nominal strength are identical.
What excipient strategies can improve tavaborole products?
The strongest commercial opportunities are improved delivery systems rather than simple reformulations that provide no measurable clinical or user benefit.
1. Preserve the reference solvent architecture
The lowest-risk generic strategy is to reproduce the reference product's solvent classes and critical quality attributes. This approach can reduce formulation-development time and limit bioequivalence risk.
Key targets include:
- Tavaborole solubility throughout shelf life
- Absence of precipitation or crystal growth
- Consistent viscosity and spreading
- Rapid drying without excessive tack
- Nail-plate penetration
- Container-closure compatibility
- Low extractables and leachables
- Acceptable odor and skin feel
This strategy is most suitable for an ANDA product competing primarily on price.
2. Reduce irritation while maintaining penetration
Alcohol and glycols can cause erythema, dryness, burning or itching. A modified vehicle could reduce alcohol concentration or replace part of the solvent system with a lower-irritancy cosolvent.
Potential candidates include:
- Transcutol-type solvents
- Low-irritancy glycol ethers
- Propylene glycol alternatives
- Selected polyethylene glycol grades
- Volatile silicone or hydrofluoroalkane components, where solubility permits
- Film-forming polymers at low concentration
The formulation must avoid reducing tavaborole delivery into the nail. A lower-irritancy system with weaker penetration would have limited commercial value unless it produces a meaningful adherence benefit.
3. Add film-forming functionality
A thin film could prolong residence on the nail and reduce loss from washing, footwear and abrasion. Candidate technologies include acrylate copolymers, cellulose derivatives and other nail-compatible polymers.
The principal development risks are:
- Slower drying
- Visible residue
- Peeling or flaking
- Reduced active release
- Difficult removal
- Changes in dose uniformity
- Increased manufacturing complexity
A film-forming product could command a premium if it reduces daily application failures. The product would need evidence that the film improves drug exposure or treatment persistence without making application less acceptable.
4. Develop a brush, pen or metered applicator
The current solution format leaves room for packaging innovation. A precision brush, pen or metered pump could improve dosing around the nail folds and under the distal nail edge.
Commercial benefits could include:
- Less product waste
- Cleaner application
- Improved portability
- Lower risk of bottle contamination
- Better patient adherence
- More reliable delivery to the hyponychium
Packaging changes can create meaningful differentiation without changing the active formulation. They also introduce device-combination-product requirements, container-closure testing and human-factors considerations.
5. Pursue sustained-release or nail-reservoir systems
A nail lacquer, microemulsion, hydrogel or nanoparticle system could create a reservoir in the nail plate. These platforms may reduce dosing frequency, but they face substantial formulation and regulatory barriers.
Potential problems include:
- Slow and incomplete drug release
- Local accumulation
- Scale-up complexity
- Increased cost of goods
- Difficult manufacturing controls
- Need for new clinical evidence
- Regulatory treatment as a reformulated product rather than a straightforward generic
A once-weekly or twice-weekly tavaborole product would have greater commercial differentiation than a daily generic, but the development program would also be materially more expensive.
What patents protect tavaborole and its formulations?
Tavaborole was originally protected by Anacor patent families covering the oxaborole compound, pharmaceutical compositions and antifungal uses. Kerydin received five-year new chemical entity exclusivity that expired in 2019. [1,3]
The commercial patent analysis should separate four categories:
| Protection category |
Relevance to tavaborole |
| Compound patents |
Protect tavaborole or related oxaborole structures |
| Composition patents |
Cover solutions, solvent systems, concentrations or dosage forms |
| Method-of-use patents |
Cover treatment of onychomycosis or application regimens |
| Packaging or device patents |
Cover applicators, containers or delivery systems |
The original compound protection is less important to current entry economics than any surviving formulation, use or device claims. Generic applicants typically assess Orange Book-listed patents, non-Orange Book patent families, regulatory exclusivity and litigation risk before filing.
What is the Orange Book status of Kerydin?
Kerydin's FDA regulatory exclusivity is expired. The FDA Orange Book remains the operative source for any currently listed patents and their use codes. [3] A generic applicant must evaluate listed patents through the ANDA Paragraph IV process where applicable.
A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. The brand holder can file an infringement action within 45 days, triggering a potential 30-month stay of approval under the Hatch-Waxman framework. [4]
When does tavaborole lose exclusivity?
Tavaborole's five-year new chemical entity exclusivity ended in 2019, five years after FDA approval. Generic entry therefore does not depend on waiting for NCE exclusivity to expire. The practical entry date depends on:
- Remaining Orange Book patents
- Paragraph IV litigation
- First-filer status
- FDA review timing
- Paragraph III patent certifications
- Settlement terms
- Manufacturing readiness
- Commercial willingness to launch at a discount
Tavaborole has no biologic component, so biosimilar regulation does not apply. Competition will come through ANDA applicants, authorized generic arrangements, reformulated products and potentially compounded alternatives, although compounded products are not substitutes for FDA-approved generic products in regulatory status.
What generic entry risks exist for Kerydin?
The primary generic risk is price erosion. A topical solution with a well-defined active ingredient and an established reference product can attract multiple ANDA applicants once patent barriers are manageable.
Likely generic launch scenarios
| Scenario |
Commercial result |
| One approved generic |
Moderate price reduction; brand may retain specialty-pharmacy access |
| Several approved generics |
Rapid reimbursement pressure and significant net-price erosion |
| First-filer Paragraph IV settlement |
Delayed entry followed by concentrated competition |
| Authorized generic |
Brand or licensee controls part of the low-price segment |
| Differentiated reformulation |
Premium pricing remains possible if adherence or penetration improves |
| No successful generic launch |
Brand retains value only if patents, supply constraints or commercial strategy delay entry |
The most exposed revenue comes from chronic prescriptions requiring nearly one year of therapy. Annual treatment duration also increases refill friction, abandonment and payer sensitivity. A generic with a lower acquisition cost can compete effectively even without superior clinical performance.
What commercial opportunities exist for tavaborole excipients?
The most attractive opportunities fall into three segments.
Generic excipient supply
Large-volume opportunities exist for pharmaceutical-grade propylene glycol, alcohol and diethylene glycol monoethyl ether. Suppliers that can provide consistent impurity profiles, low-peroxide material, validated microbial control and reliable global supply can compete for generic manufacturing contracts.
Premium nail-delivery platforms
A reformulated tavaborole product could target patients who discontinue treatment because of irritation, messiness or inconvenient application. The strongest value proposition would combine:
- Lower local irritation
- Improved nail penetration
- Faster drying
- More precise dosing
- Reduced application frequency
- Better cosmetic acceptability
A delivery platform with proprietary composition or packaging claims may create a more durable commercial position than an unprotected excipient substitution.
Combination products
Tavaborole could be evaluated with keratolytics, nail-softening agents or other topical antifungals. Combination development faces safety, compatibility and clinical-design challenges. The commercial rationale is strongest where the second component improves nail access or addresses mixed fungal pathology.
How does tavaborole compare with competing topical antifungals?
| Product |
Active ingredient |
Typical regimen |
Vehicle opportunity |
| Kerydin |
Tavaborole 5% |
Daily for 48 weeks |
Solvent optimization, film-forming delivery, applicator |
| Jublia |
Efinaconazole 10% |
Daily for 48 weeks |
Low-surface-tension solution and brush delivery |
| Penlac |
Ciclopirox 8% |
Daily with periodic removal |
Lacquer adherence and removal burden |
| Oral terbinafine |
Terbinafine |
Shorter systemic course |
No topical excipient opportunity; systemic safety limits use |
Tavaborole's main formulation advantage is its simple solution format. Its main commercial weakness is the long treatment period and modest complete-cure rate. A formulation that improves penetration or persistence could compete against efinaconazole and ciclopirox without changing the active mechanism.
What manufacturing and IP barriers affect tavaborole products?
Manufacturing is relatively accessible compared with sterile injectables or biologics. The principal controls are:
- Accurate tavaborole assay and uniformity
- Solvent purity
- Water control
- Peroxide and aldehyde limits
- Compatibility with plastic packaging
- Closure integrity
- Evaporation control
- Crystal-growth monitoring
- Microbial quality
- Fill-volume accuracy
The most defensible intellectual property is likely to arise from measurable performance: a defined solvent ratio, a nail-penetration profile, a specific applicator, reduced irritation, reduced dosing frequency or a clinically demonstrated adherence benefit.
A generic that copies the reference formulation may have limited patent differentiation but lower regulatory risk. A reformulator can seek stronger market protection, but the product may require a new drug application, 505(b)(2) pathway or additional clinical evidence depending on the extent of change and the claims pursued.
Key Takeaways
- Tavaborole is marketed as Kerydin 5% topical solution for once-daily treatment of toenail onychomycosis.
- The reference vehicle contains alcohol, propylene glycol and diethylene glycol monoethyl ether.
- Excipient selection controls solubility, nail penetration, drying time, irritation and adherence.
- Tavaborole's five-year FDA new chemical entity exclusivity expired in 2019.
- Current entry risk depends primarily on Orange Book patents, Paragraph IV litigation, ANDA approvals and settlement terms.
- The lowest-risk opportunity is a reference-like generic solution.
- The highest-value opportunity is a differentiated product with improved penetration, reduced irritation, lower dosing frequency or a superior applicator.
- Biosimilar competition does not apply because tavaborole is a small molecule.
- Manufacturing barriers are manageable, but solvent purity, packaging compatibility and crystal-growth control remain important.
- Excipient suppliers can compete through pharmaceutical-grade quality, reliable supply and validated nail-delivery performance.
FAQs
Can propylene glycol be removed from a tavaborole formulation?
Yes, but removal can change tavaborole solubility, viscosity, drying behavior and nail penetration. A substitute vehicle requires comparative pharmaceutical and regulatory evaluation.
Is diethylene glycol monoethyl ether essential to tavaborole efficacy?
It is not necessarily chemically essential, but it is a critical performance excipient in the reference formulation because it contributes to solvent capacity and penetration through keratinized tissue.
Can a generic tavaborole product use a different applicator?
Yes. A different brush, pen or metered applicator may be commercially attractive, but the sponsor must demonstrate dose delivery, container compatibility, stability and appropriate regulatory equivalence.
Is a weekly tavaborole formulation commercially feasible?
It is technically possible as a development objective, but it would likely require a sustained-release or nail-reservoir system and a regulatory pathway beyond a simple reference-like ANDA.
Does tavaborole have biosimilar competition?
No. Tavaborole is a small-molecule drug. Competitive products would be generics, authorized generics, reformulations or other topical and oral antifungal therapies.
References
- U.S. Food and Drug Administration. (2014). Kerydin (tavaborole) topical solution, 5% prescribing information.
- Elewski, B. E., Aly, R., Baldwin, S. L., et al. (2015). Efficacy and safety of tavaborole topical solution, 5%, in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology, 73(1), 62-69.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355 and 35 U.S.C. §§ 156, 271, 282.
